Apple and Masimo are back in a California court this week for a bench trial that will see Masimo arguing that Apple illegally ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

GE HealthCare and Masimo have signed an agreement for the integration of Masimo Signal Extraction Technology (SET) pulse oximetry with the Portrait Mobile wireless and wearable patient monitoring ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside. Analyzing Ratings Among Peers The below ...

October 22, 2024--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5 ...

--(BUSINESS WIRE)--Masimo Corporation (Nasdaq ... its third quarter 2024 investor conference call today, November 5, 2024 at 4:30 p.m. Eastern Time. To register for the conference call and ...